Editorial review
Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.
USP General Chapter <797> is a United States Pharmacopeia (USP) standard that sets sterility, environmental, and testing requirements for compounded sterile preparations, such as injectable medications and eye drops. Ketamine troches are lozenges meant to dissolve under the tongue, a non-sterile oral dosage form, so they fall under a different chapter: USP <795>, Pharmaceutical Compounding, Nonsterile Preparations. If a compounding pharmacy tells you your troches are made under USP <797>, that is worth a follow-up question, because the standard that actually governs troche production is USP <795>.
The United States Pharmacopeia is an independent, nonprofit scientific organization that sets quality, purity, and compounding standards used across U.S. pharmacy practice. Its chapters are numbered, and the number tells you what kind of preparation the rules cover, not how strict they are.
Quick Answer
USP <797> applies to sterile compounded drugs like injectables, not to ketamine troches. Ketamine troches are non-sterile oral lozenges compounded under USP <795>, which sets its own rules for ingredient testing, potency, beyond-use dating, and record keeping. A pharmacy that says it follows USP <797> for troches is likely referring to broader facility accreditation rather than the chapter that governs the lozenge itself. Ask your prescriber or pharmacy which USP chapter applies to confirm you're getting an accurate answer.
Why Sterility Isn't the Relevant Standard for Troches
Sterile compounding rules exist because injectable and ophthalmic drugs bypass the body's normal defenses, so any microbial contamination goes straight into the bloodstream, spinal fluid, or eye tissue. A troche dissolves in the mouth and is absorbed through the oral mucosa; it does not puncture skin or enter sterile body cavities. That is why USP <795>, not USP <797>, governs the quality controls for troches, along with capsules, creams, and other nonsterile dosage forms.
USP <795> still sets real requirements. It covers ingredient sourcing and identity testing, potency and stability testing, beyond-use dating (the expiration window a compounded product is assigned), documented master formulation records, and facility cleanliness standards appropriate to nonsterile work. You can read more about how these rules apply specifically to lozenges in our guide to USP 795 compounding standards for ketamine troches.
What This Means for Your Pharmacy Choice
Ketamine troches are compounded off-label under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits pharmacies to prepare individualized medications based on a prescriber's order. They are not FDA-approved products; the only FDA-approved ketamine-derived treatment for treatment-resistant depression is esketamine (Spravato), delivered as a nasal spray under direct clinical supervision. You can review the distinction in more detail in our overview of the FDA status of compounded ketamine troches.
Because compounded troches don't go through FDA premarket review, the compounding pharmacy's own quality controls, meaning correct USP chapter compliance, accreditation, and testing practices, are what stand between you and a product with unreliable potency. Understanding active ingredients in ketamine troches and how they're formulated can help you ask more informed questions of your pharmacy.
Compare troche options
Compare troches with other ketamine routes and safety considerations.
Compare optionsUSP <795> vs. USP <797>
| Feature | RecommendedUSP <795> | USP <797> |
|---|---|---|
| Applies to | Nonsterile preparations | Sterile preparations |
| Example dosage forms | Troches/lozenges, capsules, creams | Injectables, IV bags, eye drops |
| Route of administration risk | Oral mucosa, no sterile barrier crossed | Bloodstream or sterile cavity exposure |
| Relevant to ketamine troches | Yes | No |
Questions to Ask Your Compounding Pharmacy
- Confirm the pharmacy compounds under USP for oral/sublingual dosage forms
- Ask whether the pharmacy holds Pharmacy Compounding Accreditation Board (PCAB) accreditation
- Request the beyond-use date assigned to your specific troche formulation
- Ask what potency and stability testing the pharmacy performs on each batch
- Confirm the pharmacy is licensed in your state and operates under a valid 503A prescription order
Educational Content, Not Medical Advice
This article explains USP compounding chapters for general understanding. It is not medical advice and does not substitute for guidance from your prescriber or pharmacist about your specific treatment plan. Compounded ketamine troches are prescribed off-label and are not FDA-approved products.
If you're comparing compounded troches to other options, our compounded vs. brand-name esketamine comparison walks through the practical differences in oversight and approval status. For a broader orientation to troche basics, including how dosing and storage fit together, see the complete guide to ketamine troches. And if side effects or safety questions come up as you evaluate a pharmacy or provider, our ketamine troche safety guide covers what to watch for and when to contact your prescriber.
Find a Legitimate Troche Provider
Get plain-language help understanding what a compliant compounding pharmacy and prescriber relationship looks like before you start treatment.
Frequently Asked Questions
No. USP <797> governs sterile preparations only. The raw ketamine powder used by a compounding pharmacy may be handled under general safe-handling procedures, but the finished troche itself is regulated under USP <795> as a nonsterile oral dosage form.
The Pharmacy Compounding Accreditation Board (PCAB) is a voluntary accreditation program administered by the National Association of Boards of Pharmacy that verifies a compounding pharmacy meets quality standards, including USP chapter compliance. It is not required by law in every state, but it is one signal of a pharmacy's documented quality controls.
No. Compounded ketamine troches are prescribed off-label under Section 503A of the Federal Food, Drug, and Cosmetic Act. The only FDA-approved ketamine-derived treatment is esketamine (Spravato), a nasal spray approved for treatment-resistant depression and administered under direct clinical supervision.
The United States Pharmacopeia's compounding resource hub outlines the chapter's scope, and the FDA's human drug compounding page explains how USP chapters interact with federal compounding law.
Share
Related Reading
Contact Ketamine Troche
Send corrections, provider questions, or advertising inquiries.